First study in humans to show a link between activity in the amygdala to subsequent CV events, likely via upregulation of haemopoietic tissue activity and increased atherosclerotic inflammation.
In elderly patients with elevated SBP and pulse pressure, sacubitril/valsartan was superior compared with olmesartan in reducing sitting and ambulatory central aortic and brachial pressures.
In HIV-ACS patients of the EVERE2ST-HIV study, platelet reactivity and residual platelet reactivity were increased with P2Y12 receptor inhibitors and aspirin, compared to non-HIV ACS patients.
In a large, multinational, post-ACS population, most patients were not treated with high-potency statin regimens early and late after the event which is contradictory to guidelines
In an analysis of the IMPROVE-IT study, ACS patients with a history of CABG had a greater clinical benefit of ezetimibe therapy on top of statin versus placebo, compared with patients without CABG.
A global analysis including over 8 million people revealed an increasing rate of SBP above 110 mmHg between 1990 and 2015, which accounts for an estimated 17.8 million deaths in 2015.
Association between increased plasma NT-proSST concentrations and increased risk of incident CVD and all-cause mortality in those without previous CVD, after adjusting for traditional CVD risk factors.
The agreement is for the development and commercialization of novel treatments for lowering lipoprotein(a) and apolipoprotein C-III
In a large analysis of 11 population-based cohorts, different physical activity patterns were associated with reduced risks for all-cause-, CVD-, and cancer mortality.
In four studies with patients with heterozygous familial hypercholesterolemia, alirocumab resulted in significant LDL-C-lowering and was well tolerated.
HFpEF patients with diabetes have worse quality of life, higher NT-proBNP levels, more echocardiographic abnormalities and worse outcomes compared with those without diabetes.
Dabigatran, rivaroxaban and apixaban users were less often associated with liver injury hospitalisation compared to warfarin and several variables could predict this.